Healthcare shares were flat to lower in pre-market trade
In healthcare stocks news, Sarepta Therapeutics (
) was lower by 1% in pre-market trade after reporting Q4 results
that were weaker-than-expected.
The drug developer said its non-GAAP net loss widened to $0.77
per share from a loss of $0.34 the year earlier compared to the
$0.71 average loss expected by analysts polled by Capital IQ. Sales
fell to $2.6 million from $7.23 million, missing the $4.2 million
And, NxStage Medical (
) reported Q4 earnings that were slightly ahead of analysts'
expectations and predicted net losses in Q1 and the full year that
were wider than the consensus estimate.
The maker of dialysis products said its net loss in the quarter
was $0.08 per share, down from a $0.04 loss the year earlier and
compared to the loss of $0.09 average estimate from analysts polled
by Capital IQ. Sales rose 7% to $69.4 million, exceeding the $67.8
Finally, Pacira Pharmaceuticals, Inc. (
) was up 5% after it said its Phase 3 clinical trial assessing the
safety and efficacy of EXPAREL in femoral nerve block for total
knee arthroplasty met its primary efficacy endpoint.
This pivotal Phase 3 trial evaluated 183 patients who were
randomized to receive either 266 mg of EXPAREL or placebo, with all
patients offered rescue narcotics as needed.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.